ONCS | OncoSec Medical Incorporated

Healthcare sector

• Summary
• Earnings Call
• Events
• Charts
• Historical Data
• Dividends
• Upgrades
• Profile

Category: Biotechnology company

• Industry: Biotechnology

Quick infos

• Headquarters:   California, United States

Trade prices

• Volume:
• Market Cap: 32.71M
• Prev closed: 3.75
• Open: 4.35
• High: 5.27
• Low: 4.08
• 52 week low: 3.52
• 52 week high: 19.6
• Dividends:

Next ER: June 27, 2023  After Market Closes

Top Stories (ONCS)

Company Profile

OncoSec is a late-stage biotechnology company developing immunotherapy cancer treatments using our plasmid DNA delivery platform.

Earnings History

Date	EPS / Forecast	Revenue / Forecast
March 14, 2023	-2.65 / -0.1522	- / -
December 9, 2022	-4.5 / -8.14	- / -
October 28, 2022	-0.2087 / -0.2442	- / -
June 14, 2022	-0.16 / -0.16	- / -
June 3, 2022	- / -0.18	- / -
view more

NASDAQ - Nasdaq Stock Market

Tweets

News

News for (ONCS)

• 
  OncoSec Medical prices $3.5M stock offering
  seekingalpha.com Nov 30, 2022 10:36 pm
• 
  OncoSec provides updates on cancer programs in new filing
  seekingalpha.com Nov 23, 2022 11:10 pm
• 
  OncoSec jumps 19% after positive Phase 2 data for melanoma candidate
  seekingalpha.com Nov 11, 2022 10:17 pm
• OncoSec Releases Presentation Spotlighting the Benefits of the Proposed CGP/Sirtex Transaction and Partnership
  finance.yahoo.com Oct 12, 2020 9:00 am
• OncoSec's Visceral Lesion Applicator (VLA) Electroporation Device Demonstrates Targeted Entry and Deployment in Both Lung and Liver in Data Presented at the Society of Interventional Oncology Annual Meeting
  finance.yahoo.com Oct 12, 2020 8:46 am
• OncoSec Announces Appointment of Sandra Aung, Ph.D. as Senior Vice President, Chief Clinical Development Officer
  finance.yahoo.com Oct 12, 2020 8:30 am
• 
  OncoSec stock plummets 26% on 1-for-22 reverse stock split
  seekingalpha.com Nov 9, 2022 3:29 am
• 
  OncoSec to cut workforce by 45% as part of corporate restructuring
  seekingalpha.com Oct 5, 2022 5:42 am
• 
  Robert Arch joins OncoSec Medical as CEO
  seekingalpha.com Apr 29, 2022 8:07 pm
• 
  OncoSec appoints new finance chief
  seekingalpha.com Feb 23, 2022 6:41 pm
• 
  BTIG assumes coverage of Immuno-oncology companies; OncoSec gains on Buy rating
  seekingalpha.com Oct 15, 2021 5:47 pm
• 
  Galectin Therapeutics, ReShape Lifesciences leads healthcare gainers; Sigilon Therapeutics, Aerpio Pharmaceuticals among major losers
  seekingalpha.com Jul 9, 2021 10:56 pm
• 
  Aerpio Pharmaceuticals, GBS leads healthcare gainers; Virpax Pharmaceuticals, Nephros among major losers
  seekingalpha.com Jul 8, 2021 11:05 pm
• 
  OncoSec surges 20% after teaming up with Merck for late-stage TAVO/Keytruda trial
  seekingalpha.com Jul 7, 2021 4:13 am
• 
  OncoSec names Brian Leuthner as interim chief executive officer
  seekingalpha.com Jun 25, 2021 4:34 am
• 
  OncoSec receives CE mark certification for its commercial electroporation device
  seekingalpha.com Apr 14, 2021 8:53 pm
• 
  OncoSec receives $2.5M approval in NJEDA NOL Program Tax Benefits
  seekingalpha.com Feb 23, 2021 11:35 pm
• 
  Dosing underway in OncoSec's COVID-19 vaccine candidate study
  seekingalpha.com Jan 28, 2021 12:10 am
• 
  OncoSec Medical prices $42M share offering
  seekingalpha.com Jan 21, 2021 9:40 pm
• 
  OncoSec Medical readies underwritten public offering
  seekingalpha.com Jan 21, 2021 5:59 am

Talk about OncoSec Medical Incorporated below in comments section below.

Do you think you'll buy? Do you already have active trades now?

EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above.
This profile is based on publicly available information and is intended to be informative in nature.

Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.

Other ER on Jun 27, 2023 (Same day)